90.05
+0.67%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Galenica
Its shares trade on SIX under the ticker GALE.SW. It has been listed since 7 April 2017. In the fiscal year to 31 December 2025, it reported revenue of CHF 4.14bn and net income of CHF 181.1m. At that date it held total assets of CHF 3.34bn and shareholders' equity of CHF 1.48bn.
Galenica AG engages as a health care provider in Switzerland. The company is headquartered in Bern, Bern. The company went IPO on 2017-04-07. The firm's business i divided into three business sectors: Retail, Products & Brands, and Services. The firm manages a locally established pharmacies network in Switzerland. The company develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 7 Apr 2017
- Employees
- 5,538
- Website
- galenica.com ↗
Leadership
Pay as last reported
- Dr. Markus NeuhausIndependent Chairman of the Board of DirectorsCHF 446,000
- Mr. Marc WernerChief Executive Officer, Member of the Corporate Executive CommitteeCHF 1.3m
- Dr. Thomas SzuranChief Products & Home Care, Deputy Chief Executive Officer, Member of the Corporate Executive Committee
- Ms. Pascale BrudererIndependent Vice Chairwoman of the Board of DirectorsCHF 195,000
- Mr. Julian FiessingerChief Financial Officer, Member of the Corporate Executive Committee
- Ms. Arianne HaslerChief People and Culture Officer, Member of the Corporate Executive Committee
- Mr. Lukas AckermannChief IT & Digital Business, Member of the Corporate Executive Committee
- Ms. Virginie JeschkaChief Pharmacies Officer, Member of the Corporate Executive Committee
- Mr. Andreas KochChief Wholesale & Logistics, Member of the Corporate Executive Committee
- Mr. Daniele MadonnaChief Pharmacies Category Management & Health Services, Member of the Corporate Executive Committee
- Mr. Stephan MignotChief Pharmacies Marketing, Member of the Corporate Executive Committee
- Mr. Barbara WalchliGeneral Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 91
- Environment
- 95
- Social
- 99
- Governance
- 78
- Direct emissions (scope 1)
- 6,546 t
- Energy emissions (scope 2)
- 682 t
- Value chain emissions (scope 3)
- 3,471 t
- Women in the workforce
- 74.74595%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Galenica AG has a diverse portfolio of healthcare products, including pharmaceuticals, generics, nutritional supplements, and medical devices. This wide range allows the company to cater to various customer needs and capture a larger market share.
- Galenica AG is a well-established player in the healthcare industry, with a significant market presence in multiple countries. Its strong brand reputation and extensive distribution network enable the company to maintain a competitive advantage and attract customers.
Weaknesses
- Galenica AG relies on external suppliers for raw materials and ingredients used in its products. Any disruption in the supply chain or quality issues with the suppliers could potentially impact the company's production and availability of its healthcare products.
- Although Galenica AG operates in multiple countries, its geographic diversification is still relatively limited compared to some competitors. This could make the company more vulnerable to economic downturns or regulatory changes in specific markets.
Opportunities
- The global demand for healthcare products, especially in emerging markets, is on the rise. Galenica AG can capitalize on this trend by expanding its presence in these markets and introducing innovative products that address specific healthcare needs.
- Advancements in technology, such as telemedicine and digital health solutions, present opportunities for Galenica AG to develop and offer new healthcare services. Embracing these advancements can enhance customer experience, improve operational efficiency, and drive revenue growth.
Threats
- The healthcare industry is highly competitive, with numerous pharmaceutical and healthcare companies vying for market share. Galenica AG faces the threat of rivalry from existing competitors as well as new entrants, which could impact its market position and profitability.
- The healthcare sector is subject to stringent regulations and compliance requirements. Changes in government regulations, drug pricing policies, or quality standards could pose challenges for Galenica AG, requiring the company to adapt and comply with evolving regulatory frameworks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.